MA39493A - Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci - Google Patents

Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci

Info

Publication number
MA39493A
MA39493A MA039493A MA39493A MA39493A MA 39493 A MA39493 A MA 39493A MA 039493 A MA039493 A MA 039493A MA 39493 A MA39493 A MA 39493A MA 39493 A MA39493 A MA 39493A
Authority
MA
Morocco
Prior art keywords
oxazino
benzotriazine
dione
fluorophenyl
cyclopropyl
Prior art date
Application number
MA039493A
Other languages
English (en)
Inventor
Sylvie Bretin
Maria Pueyo
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51383800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39493(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MA39493A publication Critical patent/MA39493A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA039493A 2014-04-07 2015-04-03 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci MA39493A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1453046A FR3019464B1 (fr) 2014-04-07 2014-04-07 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
MA39493A true MA39493A (fr) 2015-10-15

Family

ID=51383800

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039493A MA39493A (fr) 2014-04-07 2015-04-03 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci

Country Status (19)

Country Link
US (1) US20170027949A1 (fr)
EP (1) EP3129059A1 (fr)
JP (1) JP2017510597A (fr)
KR (1) KR20160134854A (fr)
CN (1) CN106163563A (fr)
AU (1) AU2015245416A1 (fr)
CA (1) CA2944750A1 (fr)
CL (1) CL2016002518A1 (fr)
EA (1) EA201692006A1 (fr)
FR (1) FR3019464B1 (fr)
MA (1) MA39493A (fr)
MD (1) MD20160115A2 (fr)
MX (1) MX2016013118A (fr)
PE (1) PE20170332A1 (fr)
PH (1) PH12016501982A1 (fr)
RU (1) RU2016143382A (fr)
SG (1) SG11201608152RA (fr)
WO (1) WO2015155451A1 (fr)
ZA (1) ZA201606873B (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE556710T1 (de) * 2004-01-26 2012-05-15 Cortex Pharma Inc Verbesserung der durch ampakine induzierten erleichterung von synaptischen reaktionen durch cholinesterase-inhibitoren
US8173644B2 (en) * 2007-01-03 2012-05-08 Les Laboratoires Servier 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
MX2010002890A (es) * 2007-09-20 2010-07-02 Cortex Pharma Inc 1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas.

Also Published As

Publication number Publication date
PE20170332A1 (es) 2017-04-15
MD20160115A2 (ro) 2017-02-28
EP3129059A1 (fr) 2017-02-15
US20170027949A1 (en) 2017-02-02
PH12016501982A1 (en) 2017-01-09
CN106163563A (zh) 2016-11-23
FR3019464A1 (fr) 2015-10-09
WO2015155451A1 (fr) 2015-10-15
FR3019464B1 (fr) 2016-05-06
JP2017510597A (ja) 2017-04-13
AU2015245416A1 (en) 2016-10-27
EA201692006A1 (ru) 2017-02-28
MX2016013118A (es) 2017-01-20
KR20160134854A (ko) 2016-11-23
SG11201608152RA (en) 2016-11-29
ZA201606873B (en) 2018-11-28
RU2016143382A (ru) 2018-05-07
CA2944750A1 (fr) 2015-10-15
CL2016002518A1 (es) 2017-03-17

Similar Documents

Publication Publication Date Title
IL250890B (en) Compounds for the inhibition of indoleamine-2-3-dioxygenase and pharmaceutical preparations containing them
CA2956871C (fr) Composes actifs envers des bromodomaines
WO2016011390A8 (fr) Agents d'inhibition de l'irak 4
EP3416647A4 (fr) Iminopyrimidinones substituées par n3 à titre d'agents antipaludéens
EP3434285A4 (fr) Composition pharmaceutique et ses utilisations
EP3421038A4 (fr) Composé de naphtyridine, composition pharmaceutique et leur utilisation
IL252897A0 (en) Indanyl compounds, pharmaceutical preparations and their medical uses
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
IL248773B (en) History -6,1-Naphthyridine-5,4-Dione and pharmaceutical preparations containing them
EP3291818A4 (fr) Compositions et procédés pour l'administration d'agents thérapeutiques dans le côlon
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
EP3199163A4 (fr) Composition de doxycycline dans des liposomes pour la prévention, l'amélioration et/ou le traitement de pathologies oculaires
EP3441075A4 (fr) Composition d'huile essentielle administrée par voie orale et son utilisation
EP3519387A4 (fr) Dérivés de tétrahydropyridine et leur utilisation en tant qu'agents antibactériens
EP3443951B8 (fr) Agent surgraissant et composition de soin personnel
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
ZA201607353B (en) Bicyclic derivatives and pharmaceutical composition including the same
WO2015181837A3 (fr) Nouveaux composés utilisés comme agents anti-tuberculeux
EP3204120A4 (fr) Procédés et compositions pour augmenter l'activité d'agents antifongiques
MA39493A (fr) Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci
WO2016083315A8 (fr) Utilisation d'antagonistes d'ox1r pour le traitement de maladies intestinales inflammatoires
WO2016073652A8 (fr) Iminosucres utiles pour le traitement de maladies virales
EP3094330A4 (fr) Traitement de la maladie de crohn au moyen de faibles doses de laquinimod
FR3034019B1 (fr) Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent